HC Wainwright Raises Earnings Forecast for Abeona Therapeutics

Analyst firm increases FY2025 earnings per share estimate for the biopharmaceutical company.

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

HC Wainwright, an investment research firm, has increased its FY2025 earnings per share forecast for Abeona Therapeutics Inc. (NASDAQ:ABEO), a clinical-stage biopharmaceutical company focused on gene and cell therapies. The analyst firm now expects Abeona to post earnings of $1.23 per share in 2025, up from its previous estimate of $1.22 per share.

Why it matters

Abeona Therapeutics is a promising biotech company developing innovative treatments for rare genetic disorders and debilitating skin conditions. The increased earnings forecast from HC Wainwright suggests the firm has a bullish outlook on the company's future performance and the potential success of its pipeline of therapies.

The details

In a research note, HC Wainwright analyst R. Selvaraju cited the biopharmaceutical company's strong pipeline and progress in its clinical programs as reasons for the raised earnings forecast. Abeona is currently developing separate AAV-based gene therapies for the CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, as well as an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.

  • The research note was issued on Tuesday, March 10, 2026.

The players

HC Wainwright

An investment research firm that covers Abeona Therapeutics and has a 'Buy' rating and $20.00 price target on the stock.

R. Selvaraju

The HC Wainwright analyst who increased the FY2025 earnings per share estimate for Abeona Therapeutics.

Abeona Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life-threatening rare diseases and oncology indications.

Got photos? Submit your photos here. ›

What they’re saying

“HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $1.23 for the year, up from their prior forecast of $1.22.”

— R. Selvaraju, Analyst (HC Wainwright)

The takeaway

The increased earnings forecast from HC Wainwright suggests the investment firm has a positive outlook on Abeona Therapeutics' ability to successfully advance its pipeline of gene and cell therapies for rare genetic disorders, which could lead to improved financial performance for the company in the coming years.